Arcutis Biotherapeutics filed Q1 2026 results after the close on May 6, delivering a split verdict that puts the stock's 13.5% short interest in an interesting position heading into the next trading session.
The revenue number was the highlight. Q1 sales came in at $105.4 million, ahead of the $101.3 million consensus. That continues a remarkable commercial trajectory for Zoryve — full-year 2025 revenue nearly doubled year-on-year to $376 million, following a Q4 that saw the company post its first profitable quarter. Management also upgraded full-year 2026 guidance to $480–$495 million, above the prior $455–$470 million range and well ahead of what the Street had modelled. On the earnings line, however, the company missed. EPS came in at -$0.09 versus the -$0.06 estimate, a reminder that profitability has arrived but is not yet durable.
Short positioning tells a nuanced story ahead of the post-earnings open. At 13.5% of the free float — up roughly 5% over the past month — bears have built a meaningful stake in a stock that has now beaten revenue expectations and lifted guidance. Borrow availability remains loose: cost to borrow is just 0.43% APR, near the low end of a range that has held broadly between 0.34% and 0.51% all year. That ease in the lending market suggests the short base is not under squeeze pressure. Days to cover runs at 15.6 on the official FINRA figure, though the ORTEX short score of 67.8 — up from 64.5 a week ago — flags that algorithmic short-sentiment indicators have ticked higher into this print.
Options traders were running slightly more defensive than usual into earnings. The put/call ratio edged to 0.19, sitting nearly two standard deviations above its 20-day average of 0.18 — a mild skew toward protection rather than a full-blown defensive positioning signal. For context, the 52-week high on PCR is 0.42, so the current reading is far from extreme. The signal is a nudge, not a shout.
The analyst community was broadly constructive before this print. The most recent changes — all from late February and early March 2026 — were almost uniformly target-price upgrades. TD Cowen, Guggenheim, HC Wainwright and Needham all raised targets into the $34–$36 range following Q4 results, while Mizuho trimmed modestly to $35 but kept an Outperform. Goldman Sachs holds a lone Neutral at $29. With the stock closing at $23.42, the mean target of around $34.75 implies roughly 48% upside — a wide gap that reflects either lingering uncertainty about the sustainability of Zoryve's growth, or simply that the stock has not caught up with commercial execution. Those analyst changes are now 60+ days old, so fresh reactions to the Q1 beat-and-raise will be the next data point worth watching.
Institutional ownership is orderly, with Suvretta Capital at 9.6%, Frazier Life Sciences at 7.9% and BlackRock at 7.3% among the top holders. BlackRock added 526,000 shares as recently as April 30, a constructive signal ahead of the print. On the insider side, the 90-day picture is skewed by a cluster of routine executive sales on March 2 — CEO Todd Watanabe, CFO Latha Vairavan and other C-suite members all trimmed around the same date, consistent with a scheduled selling programme rather than a directional call. A small director sale followed in April and May. Net insider activity over 90 days is a net sale of approximately $5.5 million across all insiders, but significance scores were low throughout.
The key watch now is how analysts and short sellers react to the guidance raise. A $480–$495 million 2026 revenue target at a $2.9 billion market cap implies a price-to-sales multiple around 6x — not cheap, but defensible if the Zoryve ramp continues. Whether the EPS miss is treated as a one-quarter cost artefact or as evidence that profitability is further out than bulls hope will likely define the next leg in positioning.
See the live data behind this article on ORTEX.
Open ARQT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
